Endometriosis — insights into a multifaceted entity by Amalinei, Cornelia et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 56, No. 2, 2018
pp. 61–82
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2018
10.5603/FHC.a2018.0013
www.fhc.viamedica.pl
REVIEW
Correspondence address: Prof. I.-D. Căruntu
Department of Morphofunctional Sciences I, 
“Grigore T. Popa” University of Medicine and Pharmacy, 
16, University Street, Iaşi, 700115, Romania
tel.: 0040-727003700
e-mail: irinadragacaruntu@gmail.com
Endometriosis — insights into a multifaceted entity
Cornelia Amalinei1,*, Ioana Păvăleanu1,*, Ludmila Lozneanu1, Raluca Balan1,  
Simona-Eliza Giuşcă2, Irina-Draga Căruntu1
1Department of Morphofunctional Sciences I — Histology, “Grigore T. Popa”  
University of Medicine and Pharmacy, Iaşi, Romania
2Department of Morphofunctional Sciences I — Pathology, “Grigore T. Popa”  
University of Medicine and Pharmacy, Iaşi, Romania
*Both authors equally contributed to this paper
Abstract
Firstly described at the end of nineteenth century, endometriosis remains an enigmatic disease, from etio-
pathogenesis to specific markers of diagnosis and its ability to associate with malignancies. Our review has been 
designed from a historical perspective and steps up to an updated understanding of the disease, facilitated by 
relatively recent molecular and genetic progresses. Although the histopathological diagnosis is relatively simple, 
the therapy is difficult or ineffective. Experimental models have been extremely useful as they reproduce the 
human disease and allow the testing of different potential modulators or treatment options. Due to molecular 
resemblance to carcinogenesis, applications of anti-cancer agents are currently under scrutiny. The desired goal 
of an efficient therapy against symptomatic disease, along with associated infertility and malignancies, needs 
a deeper insight into the complex mechanisms involved in endometriosis initiation, development, and progres-
sion. Current trends in genomic and proteomic approaches are useful for a more accurate classification and for 
the identification of new therapeutic targets. (Folia Histochemica et Cytobiologica 2018, Vol. 56, No. 2, 61–82)
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Abbreviations: 5-FU — 5-fluorouracil; 8-OHdG 
— 8-Oxo-2’-deoxyguanosine; ACP1 — acid phos-
phatase 1; ALCAM/CD166 — activated leukocyte 
cell adhesion molecule/cluster of differentiation 166; 
ANXA4 — annexin A4; ARID1A — AT-rich interac-
tion domain 1A; AKT — serine/threonine kinase or 
protein kinase B [PKB]; Bax — BCL-2-associated X 
protein; BCL-2 — B-cell lymphoma 2; bFGF — basic 
fibroblast growth factor; BRAF — B-raf proto-onco-
gene, serine/threonine kinase; BRCA — breast and 
ovarian cancer susceptibility protein; C — complement 
component; CA-125 — cancer antigen 125; CA 19-9 
— cancer antigen 19/9; CAMs — cell-adhesion mol-
ecules; CETP — cholesteryl ester transfer protein; 
CD — cluster of differentiation; Cdk — cyclin-de-
pendent kinase, CK — cytokeratin; CLI — chloroin-
dazole; COX-2 — cyclooxygenase-2; CTNNB1 — cat-
enin (cadherin-associated protein) beta 1; CYP12A1 
— cytochrome P450 family 17 subfamily A member 1; 
DAPK1 — death-associated protein kinase 1; DNA 
— deoxyribonucleic acid; DRD2 — dopamine recep-
tor D2; E2 — estradiol; EGF — epidermal growth 
factor; EMT — epithelial-mesenchymal transition; 
ENDO-I — endometriosis protein-I; ENG — en-
doglin; eotaxin (CCL11) — C-C motif chemokine 11; 
EP — prostanoid receptor (prostaglandin E recep-
tor); ER — estrogen receptor; ERK — extracellular 
signal-regulated kinases; EZH2 — enhancer of zeste 
homolog 2; FasL — Fas ligand; FGF-9 — fibroblast 
growth factor 9; FGFR — fibroblast growth factor 
receptor; FOXP3 — forkhead box P3; FSH — folli-
cle-stimulating hormone; Gn-RH — gonadotropin-re-
leasing hormone; GROa (CXCL1) — chemokine 
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(C-X-C motif) ligand 1; GSTM1 — glutathione 
S-transferase mu 1; GSTT1 — glutathione S-trans-
ferase theta 1; HER-2 — human epidermal growth 
factor receptor 2; HGF — hepatocyte growth factor; 
HIF-1a — hypoxia-inducible factor 1 alpha; sHLA-G 
— soluble human leukocyte antigen G; hMLH1 — hu-
man mutL homolog 1; HNF1-b — hepatocyte nuclear 
factor 1 homeobox B; hTERT — human telomerase 
reverse transcriptase; ICAM — intercellular adhesion 
molecule; IFN-g — interferon gamma; Ig — immu- 
noglobulin; IGF — insulin-like growth factor; 
IL — interleukin; ITGB1 — integrin beta- 1 precursor; 
JAK — Janus kinase; KRAS — Kirsten rat sarcoma 
viral oncogene homolog; LFA-1 — lymphocyte func-
tion-associated antigen 1; LH — luteinizing hormone; 
LOH — loss of heterozygosity; MCAM — melanoma 
cell adhesion molecule; MCP-1 — monocyte chemo-
tactic protein 1; MEK — mitogen-activated protein 
kinase; MIF — macrophage migration inhibitory 
factor; miRNA — microRNA; MLH1 — human 
MutL homolog 1; MMP — matrix metalloproteinase; 
MoAb — monoclonal antibody; MSC — mesen-
chymal stem cell; mTOR — mechanistic target of 
rapamycin; MT5-MMP — membrane-type 5-MMP; 
MVD — microvascular density; NFkB-1 — nuclear 
factor of kappa light chain enhancer in B-cells; NK 
— natural killer; OBHS — oxabicycloheptene sul-
fonate; Oct-4 — octamer-binding transcription factor 
4; P4 — progesterone, PAI — plasminogen activator 
inhibitor; PD-ECGF — platelet-derived endothelial 
cell growth factor; PDGF — platelet-derived growth 
factor; PDGFRB — platelet-derived growth factor 
receptor beta; PDTC — pyrrolidine dithiocarbamate; 
PGE2 — prostaglandin E2; PGF — placental growth 
factor; PGP9.5 — ubiquitin C-terminal hydrolase 
L1; PI3K — phosphatidylinositol 3-kinase; PI3KCA 
— phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha; PPAR-g — peroxisome prolif-
erator-activated receptor gamma; PR — progesterone 
receptor; PTEN — phosphatase and tensin homolog; 
PTPN22 — protein tyrosine phosphatase, non-re-
ceptor type 22; r-hTBP-1 — recombinant human 
tumor necrosis factor binding protein-1; RANTES 
(CCL5) — chemokine (C-C motif) ligand 5; SDF1 
(CXCL12) — C-X-C motif chemokine ligand 12; 
sICAM — soluble intercellular adhesion molecule 1; 
SMAD — mothers against decapentaplegic homolog 
1 (Drosophila); StAR — acute steroidogenic regulato-
ry protein and aromatase; STAT — signal transducer 
and activator of transcription; TGF-b — transforming 
growth factor beta; Th — T helper cells; TIMP — tis-
sue inhibitor of metalloproteinase; TNF-a — tumor 
necrosis factor alpha; TNFR — tumor necrosis fac-
tor receptor; TSG — tumor suppressor gene; TSH 
— thyroid-stimulating hormone; uPA — uroki-
nase-type plasminogen activator; VEGF — vascular 
endothelial growth factor; VEGFR — vascular en-
dothelial growth factor receptor; WNT4 — wnt family 
member 4; WT1 — wilms tumor 1; ZNF217 — zinc 
finger protein 217
Introduction: definition and epidemiology
The first histopathological description of endome-
triosis was given by Von Rokitansky, as early as 
1860 [1]. By 1896, the name of “endometriomas” 
or “adenomyomas” had been proposed, due to the 
lesion resemblance to the mucous membrane of the 
uterus [2, 3]. 
Endometriosis is nowadays defined as an ectopic 
implantation of endometrial-like tissue, composed 
of both glands and stroma. Endometriosis has an 
incidence of about 2% in general population [4], 
with numerous incidental occurrences, approxi-
mately 70% of cases developing pelvic inflammatory 
disease, and 25–30% of cases being associated with 
infertility [5]. 
Endometriosis mainly involves the reproductive 
tract components (in about 75% of cases), such as 
ovaries, fallopian tubes, large, round, and uterosacral 
ligaments, uterine cervix, vagina, and recto-vaginal 
septum [5]. In about 25% of cases, this process may 
be identified in extra-reproductive organs, especially 
with intraperitoneal locations (peritoneum, Douglas 
pouch, appendix, gastro-intestinal tract, and lymph 
nodes) [6]. 
Rare extraperitoneal locations are also report-
ed in literature, such as liver [7], lung [8], pleura or 
diaphragm [9], urinary tract [10], tegument, mainly 
post-surgical abdominal scars, i.e. post C-section, nasal 
cavity [5], iliac vein wall [11], and hernial sac wall [12].
Although it is considered a benign disease, the 
endometrium acquires aggressive pathological char-
acteristics, being able to migrate, implant, proliferate, 
and grow in other sites than those genetically estab-
lished, during endometriosis development. 
Clinico-histopathological features 
Endometriosis is a highly heterogeneous entity due 
to different degrees of clinical manifestations, with 
a broad spectrum, from symptomatic cases, mani-
fested mainly with characteristic cystic lesions and 
adherences, to symptomatic cases although without 
evident lesions, and to incidentally discovered, asymp-
tomatic cases.
Gross findings are also highly variable, from small 
dispersed lesions, such as superficial or “gunpowder” 
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appearance, to cystic, red implants, or petechiae, ves-
icles, nodules, and, sometimes, polyps, depending on 
their location, duration, and association with fibrous 
adhesions [13].
A combined anatomical and histopathological 
classification recognizes three main types of en-
dometriosis: endometrioma, peritoneal, and deep 
infiltrative lesions [9]. 
Endometrial cysts or endometriomas usually in-
volve the ovaries, exhibit bilateral location in around 
one third of cases and develop until almost completely 
replacing the ovarian parenchyma [13]. They are most 
commonly associated with fibrous walls, adherences to 
neighboring structures, and usually chocolate-colored 
inspissated or semifluid content [13]. If larger than 
15 cm in diameter or associated with polypoid pro-
jections or solid areas, a developing neoplasm should 
be considered [13]. 
Peritoneal endometriosis may involve (in decreas-
ing order of frequency): ovaries (30%), uterosacral 
and large ligaments (18–24%), fallopian tubes (20%), 
pelvic peritoneum, Douglas pouch, and gastro-intes-
tinal tract [5, 6].
Deep infiltrative endometriosis has been identified 
in 30–40% of patients diagnosed with endometriosis 
[5], involving pelvis and gastrointestinal tract [6]. 
Histopathological findings have been based on the 
identification of endometrial glands surrounded by 
characteristic cellular stroma (Fig. 1A), registering an 
analogous pattern to the eutopic endometrial cycle. 
Although histopathological diagnosis can be 
relatively simply reached, the microscopic differ-
entials with ovarian endosalpingiosis [13], a lesion 
frequently overdiagnosed as endometriosis, has to be 
made. This may be achieved by the identification of 
a stromal inflammatory infiltrate, containing variable 
amount of lymphocytes, a reduced number of other 
inflammatory cells, with evident hemosiderin-laden 
macrophages (Fig. 1B), as proof of a cyclic evolution 
of the ectopic tissue, although a ceroid pigment may 
occasionally confer a pseudoxanthoma appearance 
to these cells [13]. Rarely, benign cystic lesions or 
even well differentiated adenocarcinomas may be 
included in the differential diagnosis. Currently, im-
munohistochemical profile may be useful, by CD10 
strong stromal positivity, ERb and PR-A variable 
epithelial and stromal positivity, along with Bcl-2 and 
Ki-67 epithelial and stromal positivity correlated to 
the size of the implant, supplementing the histological 
characteristics exhibited in routine staining [14]. 
The accumulation of data on endometriosis has 
been facilitated by comparative studies between native 
and experimental disease, due to a close resemblance 
of both laparoscopic findings and microscopic pat-
terns demonstrated between animal models and their 
corresponding human disease [15].
Figure 1. Distinct histological features of endometriosis. (A) Ovarian endometriosis containing endometrial glands and stroma 
in an ectopic (ovarian) location (HE, 200×). (B) Ovarian endometriosis with evident hemosiderin-laden macrophages (HE, 
200×). (C) Ovarian endometriosis associated with an area of atypical endometriosis, with a complex architecture (HE, 40×). 
(D) Ovarian endometriosis (upper field) associated with endometrioid carcinoma (inferior) (HE, 40×).
A B
C D
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Markers for diagnosis
The specific markers of endometriosis may be 
classified into three main categories (Table 1): (i) 
peritoneal and/or serum, (ii) endometrial and bio-
chemical-endometrial, and (iii) genetic types.
Peritoneal and/or serum markers are grouped into 
several categories, as follows: glycoproteins [16–19], 
growth factors [18, 20–27], proteolytic enzymes and 
their specific inhibitors [28–32], soluble adhesion 
molecules [33–37], hormones [38–43], cytokines [42, 
44–57], autoantibodies [58, 59], and environmental 
contaminants [60]. The diagnostic value of some of 
these markers has been quantified and, as a result, 
two peritoneal and/or serum cytokines may be useful 
in the diagnosis of endometriosis, such as increased 
serum IL-6 (threshold of 2 pg/ml) [49], and serum or 
peritoneal fluid TNF-a (threshold of 15 pg/ml) [49], 
although conflicting results are reported in possible 
correlation with disease stage, location, endometrial 
cycle phase, control groups, and assay type [49]. 
The endometrial and biochemical-endometrial 
markers are considered as stromal [61, 62], glandular 
[62–64], neuronal [65], proteolytic enzymes and their 
specific inhibitors [28–31, 66–70], adhesion molecules 
[34, 62, 71–74], osteopontin [75], hormonal receptors 
[38, 39, 76–80], and mesenchymal stem cells [81–85].
Genetic markers belong to variable categories, 
such as: oxidative stress genes [86], tumor suppressor 
genes [87–98], oncogenes [90, 99–103], regulatory 
genes [104, 105], DNA repair genes [93], chromo-
somal aberrations or amplifications [106–108], loss of 
heterozygosity [87, 107, 109], genetic polymorphism 
of variable genes [107, 110–119], and genome-wide 
alterations [120, 121].
The prospective clinical validation of these mark-
ers and determination of their clinical utility may lead 
to the development of a successful commercial test 
for endometriosis diagnosis. 
Past to rediscovered etiopathogenic theories 
and recent contributions
Short overview — historical hallmarks
Endometriosis is considered as the “theories disease”, 
taking into account numerous past and modern eti-
opathogenic hypotheses which have been launched 
during a long period of attempts to explain its nature 
[4, 9] (Fig. 2).
According to the past theories, endometriosis may 
result by in situ development from germinal ovarian ep-
ithelium [122], from embryonic mesonephric elements 
(Wolffian knob and Wolffian duct) [9], or from para-
mesonephric (Müllerian ducts) remnants [3, 9, 123]. 
Other hypotheses are those of metaplastic pro-
cesses, as coelomic metaplasia [9, 124–126], or meta-
plasia of the peritoneal or ovarian tissue [127, 128], 
or metaplasia of the peritoneal serosa cuff initiated 
by inflammation [9, 129] or by hormonal stimulation 
[130]. The possibility of metaplasia development, by 
differentiation of mesenchymal cells (omnipotent 
blastema) activated by substances released by degen-
erating endometrium eliminated into the abdominal 
cavity, has been also proposed [131, 132].
Figure 2. Etiopathogenic theories of endometriosis: from past to current concepts and combination of theories. Detailed 
description in the main text.
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A secondary Müllerian system development is 
suggested by another theory launched in 70s [128].
As a result of further studies and epidemiologic 
characteristics, the hypothesis of transplantation, due 
to retrograde menstruation [9, 133, 134], or to me-
chanical transplantation [9] has been later developed. 
In order to find a possible mechanism for implants’ 
development in other locations which could not be ex-
Table 1. Spectrum of markers in endometriosis diagnosis and follow-up 
Peritoneal and/or serum markers Endometrial markers Genetic markers
Glycoproteins
CA-125 [16–19], CA 19-9 [18]
Stromal
CD10 [61], Vimentin [62]
Oxidative stress
8-OHdG, [86]
Growth factors
EGF(R) [20], TGF-b [21], SF/HGF [22] 
FGF-9 [23], VEGF [20, 24],  
Angiopoietins [25], 
Glycodelin [26, 27] 
 
Glandular
CK18 [62]
Glycodelin [63, 64]
Tumor suppressor genes
PTEN [87–89], P53 [90, 91], P16 [92, 93], 
ARID1A [94–96],
WT1 [97], DAPK1 [98]
Neuronal
PGP9.5 [65]
Apoptosis
Bcl-2 (anti-apoptotic) [90, 99, 100]
Survivin (anti-apoptotic) [101]
Oncogenes
HNF1-b [102], KRAS [103]
Proteolytic enzymes and their specific 
inhibitors
MMPs/TIMPs [28–31]
Cathepsin D [32]
Proteolytic enzymes and
their specific inhibitors
MMPs/TIMPs [28–31, 66–69] 
plasminogen activators / plasminogen 
activator inhibitors [70]
Regulatory genes
PIK3CA, FGFR [104, 105]
DNA repair
hMLH1 [93]
Chromosomal aberrations
aneusomies (chrs. 1, 7, 9, and 17)
[106, 107]
Soluble adhesion molecules
E-cadherin, P-cadherin, b-catenin [33,34]
ICAM-1 [35]
sHLA-G [36]
Osteopontin [37]
Cell adhesion molecules
E-cadherin, P-cadherin, CD44 [34, 62, 
71–74]
Chromosome amplification
20q13.2, 12p12.1, 17q12, 9p21 [108]
Osteopontin [75] Loss of heterozygosity
4q, 5q, 6q, 9p, 11q, 22q,
10q23.3, 17p13.1 [87,107,109]
Hormones
E2, P4 [38, 39] 
FSH, LH, TSH [40]
Leptin [41–43]
 
Hormonal receptors
ER-b, ER-b:ER-a
[38, 39, 76, 77]
PR-A [78]
FSHR, LHR [79, 80]
Genetic polymorphism candidate genes
TP53 (17p13) [107]
VEGF (6p21-12) [110]
ACP1 (2p25) [111]
PTPN22 (1q13) [112]
DRD2 (11q32) [113]
FOXP3 (Xp11.23) [114]
GSTM1 (1p13) [115]
GSTT1 (22q11) [115]
IL-10 (1q31-32) [116]
CETP (16q21) [117]
TNF-A (6p21) [118]
CYP17A1 (10q24) [119]
Cytokines
IL-1B, IL-4, IL-6, IL-8 (CXCL8)
IL-10, IL-12, IL-17A, IL-18, IL-22 [44–51]
MCP-1 (CCL2) [52]
RANTES (CCL5) [53], 
GRO-a (CXCL1) [47], 
SDF1 (CXCL12) [54, 55], MIF [56, 57]
Mesenchymal stem cells
Oct-4 [82]
Htert, Musashi-1 [84] 
CD73 MSC/migration (NT5E) [83]
CD90 MSC/marker of T cells (THY-1) 
[81,83,85]
CD105 MSC (ENG) [83, 85]
CD140B (PDGFRB) [81]
CD146 (MCAM) [81]
CD29 MSC/adhesion molecule (ITGB1) [81]
CD44 MSC/hyaluronic acid receptor [81, 83]
CD9 MSC/angiogenesis [83]
CD41a MSC/fibrinogen receptor [83]
ALCAM/CD166 [85]
Genome-wide
VEGFR-2 (4q11-q12) [120]
WNT4 (1p36.12) [121]
Autoantibodies
IgG anti-laminin-1 [58]
anti-endometrial [59]
Environment contaminants
dioxin-like chemicals [60]
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plained by previous hypotheses, benign lymphogenous 
or hematogenous metastasis (hystero-adenosis metastat-
ica) [135, 136], or combinations of in situ development 
with endometrial transplantation and implantation or 
induction theory [132, 137] have been later proposed. 
Mechanisms and dynamics of endometriosis:  
current concepts
Considering the wide distribution of endometriosis 
locations within human organism, modern theories 
try to combine the effect of multiple contributors, as 
multi-factorial, multi-compartmental pathogenic phe-
nomena, associated with epiphenomena, as sequelae 
of the primary lesions, such as estrogen dependence 
[138], genetic susceptibility [139], and the possibility of 
direct spread by “transplantation” [9]. These process-
es are added to the incapacity of the immune system 
to neutralize ectopic endometrial cells [140–142], or 
the contextual environmental factors to intervene in 
the process, and the occurrence of congenital defects, 
such as atretic hymen. The last but not the least, the 
most plausible pathogenic mechanism is the involve-
ment of stem cells as the main “culprits” in the process 
of ectopic implantation via retrograde menses.
Retrograde menstruation and stem cells:  
a new perspective of an old theory
The currently agreed endometriosis pathogenic mech-
anism is that of retrograde menstruation, via fallopian 
tubes, a theory that had been launched by Sampson, 
as early as in 20’s. There are numerous elements that 
plead for the accuracy of this theory, as following: 
the retrograde menstruation is quite frequent, being 
estimated that viable endometrial cells may be found 
in peritoneal cavity in about 76–90% of women, in 
non-menstrual periods of time or in peritoneum, 
during menstruation or immediately after this phase 
[143]. Furthermore, the blocking of evacuation of the 
menstrual blood results in extended endometriosis 
[143]. Moreover, an endometriosis onset at prepu-
berty is quite rare [143]. 
The counterarguments of the involvement of this 
mechanism are provided by evidences that endome-
triosis may appear in areas which are inaccessible to 
menstrual reflux, including extra-peritoneal locations, 
a finding that may support lymphatic or hematoge-
nous cells migration [4].
Relatively recent data have demonstrated the oc-
currence of mesenchymal stem cells and progenitor 
endometrial cells in endometriosis and their possible 
evolution toward differentiation into nine cellular 
lines: adipocytic, osteogenic, cardiomyocytic, respira-
tory epithelium, neurocytic, myocytic, endothelial, 
pancreatic, and hepatic types [144].
Although a key role is attributed to the stem cells 
reflux into the peritoneal cavity, the microenviron-
ment factors that stimulate stem cells’ functions and 
allow the development of endometriotic implants 
are very important in the retrograde menstruation 
mechanism. 
Role of metalloproteinases
MMPs are involved in endometrial turnover and its 
pathology [145]. In endometriosis, after the attach-
ment to the ectopic sites, the epithelial endometrial 
cells invade the extracellular matrix. It has been 
demonstrated that this process occurs with the in-
volvement of MMPs, their high concentration in the 
peritoneal fluid being stimulated by TNF-a and IL-1 
[146]. Concomitantly, TNF-a inhibits TIMP-1 and 
TIMP-2 [147], resulting in an unbalanced MMPs/ 
/TIMPs ratio [17, 18, 28, 30, 31]. Increased MT5-
MMP expression [31] and alterations of the balances 
between MMP-9/TIMP-1 [30], MMP-9/TIMP-3 [28], 
MMP-3/uPA [66], VEGF/MMP-3/uPA [68], VEGF/ 
/MMP-2/CD44/Ki67 [69], PAI/TIMP-1 [70], and IL-1/ 
/MMP-1 [67] are characteristic features of endome-
triosis (Table 1).
Inflammation: cells and cytokines 
Another important feature in endometriosis patho-
genesis is attributed to the occurrence of pelvic inflam-
mation. Numerous studies have demonstrated that 
macrophages, lymphocytes, endometrial and meso-
thelial cells are capable of producing cytokines and 
inflammatory mediators such as ILs [45–51, 67, 148], 
TNF-a [149, 150], PGF2, PGE2 and thromboxane B2 
[151], MCP-1 [52, 152], RANTES [53], eotaxin [153], 
GROa [47], SDF1 [54, 55], and MIF [56, 57, 152, 154, 
155]. These cytokines recruit numerous cellular types, 
such as macrophages, lymphocytes, eosinophils, mast 
cells, and endometrial cells into the peritoneal cavity. 
This process is followed by cascade of events leading 
to the stimulation of endometriotic cells prolifera-
tion, along with their adhesion to ectopic substrates, 
angiogenesis, and stimulation of the release of other 
cytokines and chemokines, furthermore amplifying 
their effects.
Peritoneal macrophages seem to have the highest 
capability of secreting various types of cytokines and 
inflammatory mediators. Macrophages amplify the 
activity of COX-2 and PGE2, which results in VEGF 
stimulation in endothelial cells of endometriotic 
implants, together with that of StAR, resulting in an 
increased estrogen level in the endometrial tissue 
[23, 156–160]. Estrogens and PGE2 are inducing 
FGF-9 expression that activates endometrial cells 
proliferation, in a parallel manner to the stimulation 
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of angiogenesis and apoptosis inhibition [23]. PGE2 
suppresses the activity of phagocytes, allowing the 
development of endometriotic implants [23] (Fig. 3). 
NK cells have been also incriminated in endome-
triosis pathogenesis. The hypothesis of an inefficient 
clearance of the endometrial cells from the peritoneal 
cavity has been proposed [161, 162], due to peripheral 
and peritoneal NK cells failure to eliminate autologous 
dendritic cells [163] expressing self-endometrial anti-
gens what results in their presentation to autoreactive 
T cells and the production of auto-antibodies [164].
Lymphocytes are also involved in various cytokines 
production with potential role in endometriosis de-
velopment. Peritoneal fluid Th2 cells were shown to 
stimulate the secretion of IL-4 and IL-10, mainly by 
peritoneal macrophages, resulting in an aberrant sup-
pression of cell-mediated immunity what may enable 
implantation of endometrial cells in peritoneum [165]. 
Moreover, the NK cell-mediated cytotoxicity, man-
ifested by lymphocytes adherence to endometrial cells 
by LFA-1 — ICAM-1 pathway and their presentation 
as targets to NK cells, may fail in endometriosis. This 
finding has been demonstrated by an in vitro study [166] 
and later on confirmed by flow cytometry in human 
endometriosis [167]. According to this possible mecha-
nism involved in endometriosis pathogenesis, sICAM-1 
may bind to LFA-1 expressing lymphocytes, preventing 
endometrial cells recognition by lymphocytes and, fur-
thermore, preventing NK-mediated cytotoxicity [166]. 
Consequently, endometriosis is characterized by the 
inability of immune cells to send death signals to endo-
metrial cells and/or the ability of ectopic endometrial 
fragments to avoid cellular death due to an increased 
expression of anti-apoptotic molecules [168].
TNF-a, a pro-inflammatory cytokine, is also 
produced by macrophages, exhibiting elevated levels 
in the peritoneal fluid [36, 169] and serum [169] in 
endometriosis patients. It has been shown recently 
that TNF-a-induced IKKb complex activation leads 
to the initiation and progression of endometriosis, 
by enhancing the viability of the ectopic epithelial 
cells but not eutopic epithelial cells, or endometrial 
stromal cells [170]. 
MIF, another cytokine, shows a high level in 
the peritoneal fluid, in circulation, and in perito-
neal macrophages, its secretion being induced in 
endometriosis by estrogens [171]. MIF stimulates 
endothelial cell proliferation, endometriotic lesion 
survival, expression of PGE2, COX-2, VEGF, IL-8, 
MCP-1, aromatase, and reciprocally stimulates TNF-a 
in endometrial cells [56, 152, 158, 172]. ISO-1, MIF 
antagonist, is responsible for a significant reduction in 
endometriotic lesion size, in experimental models, by 
inhibiting cell adhesion, tissue remodeling, angiogen-
esis, and inflammation, in addition to alteration of the 
balance between pro- and anti-apoptotic factors [155].
Figure 3. Pivotal role of macrophages in the development of endometriosis results from amplifying the activity of COX-2 
and PGE2 production, stimulation of VEGF, StAR, IL-8 and MCP-1 secretion, increased estradiol (E2) level and FGF-9 
synthesis, which leads to endometrial cells proliferation, stimulation of angiogenesis, and apoptosis inhibition. MIF, induced 
by local estrogen reciprocally stimulates TNF-a in endometrial cells. PEG2 acts as an inhibitor of phagocytosis. Furthermore, 
altered ER expression of estrogen receptors (ER) stimulates the cascade of events. Detailed description in the main text.
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Hormones and hormone-like substances  
in the pathogenesis of endometriosis 
Steroid hormones play an important role in endo-
metrial physiology and their unbalanced activity is 
involved in endometrial pathology, including endo-
metriosis. 
In this regard, it has been demonstrated that the 
driving factor of the production of cytokines in endo-
metriosis is the altered responsiveness to progester-
one, showing a characteristic very low expression of 
progesterone receptor A (PR-A) and the absence of 
PR-B in mice models [173], and in a similar way with 
decreased PR-B/A ratio and reduced PR-B immu-
noreactivity, demonstrated in human endometriosis 
[78, 174]. 
Supplementary, the increased local estrogen lev-
els further drive the endometriotic lesion phenotype 
and increased cytokine expression and apoptosis in 
a murine endometrium [175]. Hormonal dependence in 
endometriosis is demonstrated by an increased ER-b 
expression (approximately 100 times more than that 
of eutopic endometrium), due to altered methylation 
in the ESR2 gene promoter [174]. ER-b overexpres-
sion suppresses ER-a expression and, furthermore, 
leads to an abnormally high ER-b/ER-a ratio, which 
is responsible to a reduced expression of PR and an 
increased COX-2 expression [38, 39, 77, 171]. ER-b 
activation results in the stimulation of MIF expression 
and production in the cultures of human endometrial 
cells [171]. In experimental endometriosis model, 
ER-b seems to be responsible for the inhibition of 
endometriotic cell apoptosis and the increased cytokine 
production, such as MCP-5, IL-1b, and IL-16, which re-
sults in enhanced cell adhesion and proliferation [175].
Stimulation of COX-2 activity by MIF results in 
the increased secretion of PGE2 that is considered 
a master regulator of endometriosis on the basis of its 
pro-inflammatory actions documented by its elevated 
levels in human endometriotic tissue and in peritoneal 
fluid [158, 176]. 
Angiogenesis in endometrial tissue
The angiogenic activity is stimulated in endometriosis 
by a large spectrum of angiogenic factors such as IL-1 
[177], IL-6, IL-8, VEGF [178], ENDO-I (an endo-
metrial haptoglobin homologue) [179], angiogenin 
[180], pleiotrophin, midkine [181], TNF-a [182], 
PGF [183], angiopoietin [25], and glycodelin [26, 27]. 
Moreover, in endometriosis the physiological angio-
genic activity is supplemented by the co-existence of 
pathologic angiogenesis, immune suppression, and 
immune activation [184]. Environmental factors, such 
as dioxins, may be also responsible for an increased 
angiogenesis [60].
VEGF-A role is demonstrated by its increased 
concentrations in serum, peritoneal fluid, and endo-
metrium of patients with endometriosis [17, 185, 186]. 
For instance, it was found that high levels of serum 
VEGF-A are useful for the diagnosis and follow-up 
in advanced stage of endometriosis [17]. Moreover, 
it was confirmed that the expression of VEGF-A gene 
was higher in peritoneal endometriosis compared with 
normal peritoneum [185].
One of the tools to assess angiogenesis in endome-
triosis is the measurement of vascular surface density 
(microvessel density or mean vascular density, MVD) 
[187]. An in vivo study, using transvaginal color and 
power Doppler, has demonstrated the correlation 
between high MVD and pelvic pain in patients with 
endometriosis [188]. This finding has been validated 
by immunohistochemical evaluation of CD34-labeled 
vessels [24, 188]. Although the active lesions showed 
a high mitotic index and increased MVD in implants, 
no significantly increased VEGF expression has been 
found, suggesting the involvement of other angiogenic 
factors [24]. 
Apoptosis
An apoptosis evasion mechanism has been demon-
strated in endometriosis, allowing the development of 
ectopic implants. This particular mechanism has been 
characterized by increased expression of anti-apop-
totic Bcl-2 along with decreased pro-apoptotic Bax 
expression [99, 100]. Apoptosis may be also regulated 
by Fas ligand (FasL) by its binding to cell membrane 
receptor, Fas. FasL binding results in extrinsic (au-
tocrine or paracrine) induction of apoptosis [189]. It 
was found that in cultured human endometrial stromal 
cells IL-8 up-regulated FasL protein expression and 
decreased apoptosis rate [189], the latter found in hu-
man endometrial tissue was associated with increased 
mRNA levels of survivin and MMPs [101]. 
Multistep development of endometriosis
The results of numerous studies in humans and in an-
imal models allowed proposing a multistep etiopath-
ogenic mechanism of endometriosis [50, 190–197]. 
Following retrograde menstruation which is the 
triggering phenomena responsible for an increased 
number of endometrial cells in peritoneal fluid, other 
associated mechanisms are contributing to immune 
surveillance failure (i.e. decreased NK cytolytic [46] 
and cytotoxic [162, 198] activity, ICAM-1 secretion 
[35]), that is further supplemented by decreased apop-
tosis of endometriotic cells [175, 199]. The next stage 
is marked by the localization of refluxed endometrial 
cells in the peritoneal cavity, followed by increased 
number of activated macrophages, increased secretion 
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of proinflammatory cytokines, such as IL-1b, IL-6, 
IL-8, IL-12, IL-17A, IL-18, IL-22 [44–52] and TNF-a 
[42, 146, 170], chemokines (e.g. MCP-1 [42, 52] and 
RANTES [53, 200]), and growth factors, such as EGF, 
FGF-9, TGF-b, and HGF [20–23]. The following step 
is the adherence of ectopic endometrium, followed 
by implantation and invasion, being associated with 
the stimulation of TGF-b, IL-1, TNF-a, along with 
MMPs and TIMPs secretion [28–31, 42, 50, 201, 202].
After the ectopic implantation and invasion, oth-
er processes take place: stimulation of angiogenesis 
due to enhanced levels of IL-1, IL-6, and VEGF, 
decreased immune surveillance, increased presenta-
tion of self-antigens by dendritic cells, T and B cells 
activation, elevated levels of autoantibodies, and pos-
itive feedback enhancing inflammation and immune 
responses [141].
These cascading events are responsible by the 
continuous development and persistence of endo-
metriosis. The available evidence strongly suggests 
that pivotal factors can be attributed to cytokines and 
growth factors produced by activated macrophages 
which not only fail to eliminate but promote devel-
opment of endometriosis. 
Endometriosis versus carcinogenesis
Relationships between endometriosis  
and malignancy 
As early as in 1927, the idea linking endometriosis 
with malignant transformation has been hypothesized 
[203], mainly for the ovarian location. Since then, 
numerous studies have demonstrated the overlap of 
definition criteria of malignant phenotype with those 
of endometriosis. Results of meta-analyses revealed 
their increased association [204, 205].
Clinicopathological, molecular, and genetic ev-
idences support the hypothesis of endometriosis as 
a neoplastic process, with a potential to malignant 
transformation. The first evidence is that of the com-
mon features shared by these entities that are both 
able to disseminate, to invade, and to form distant 
implants [206]. Moreover, a significant association of 
endometriosis with clear cell and endometrioid ovar-
ian carcinomas has been reported [87, 95, 103, 104, 
106, 207–211], e.g. 30–55% and 30–40%, respectively 
[206]. Furthermore, an increased incidence of concur-
rent primary malignancy, i.e. endometrial carcinoma, 
in endometriosis-associated ovarian malignancies 
suggests common molecular pathways in both loca-
tions [212]. A plethora of phenomena are common 
in sporadic cancer and endometriosis, being deter-
mined by complex interactions between hereditary 
polygenic alleles of low penetrance (polymorphism), 
acquired genetic alterations, leading to a “signature” 
of mutations, and microenvironment “permissive” 
factors, expressed by hormonal influences and chronic 
inflammation [44, 210, 212]. The current molecular 
techniques of genetic, transcriptomic and proteomic 
profiling allow for better characterization of corre-
lations between genetic and local milieu alterations 
and transition process from normal endometrium to 
malignant transformation. 
A large spectrum of tumors and tumor-like 
conditions associated with endometriosis has been 
described, such as polypoid endometriosis, benign 
tumors (such as endometrioid adenoma, adenofibro-
ma, cystadenofibroma, and cystadenoma), premalig-
nant changes (i.e. atypical endometriosis) (Fig. 1C), 
borderline tumors (e.g. endometrioid cystic adenofi-
broma and endometrioid cystadenofibroma), and 
malignant tumors, such as endometrioid adenocar-
cinoma (Fig. 1D), with squamous elements or with 
clear cell elements, low-grade and high-grade stromal 
sarcoma, and malignant tumors with mixed compo-
nents (i.e. adenosarcoma and carcinosarcoma) [109, 
206, 212–215].
Another criterion in favor of a relationship between 
endometriosis and malignancies is that endometri-
osis consists of a monoclonal tissue development, 
acquiring many of the cellular characteristics of ma-
lignant transformation [4]. Furthermore, the analysis 
of common features of endometriosis and tumors 
has revealed that endometriosis can be regarded 
as an estrogen-dependent neoplasm with an estro-
gen-induced signaling mechanism characterized by 
increased production of estrogens [38, 39], increased 
P450 cytochrome aromatase activity [171], increased 
activity of StAR [156], increased PGE2 production 
[156, 158], increased estrogen responsivity by ER-b 
overexpression, decreased ER-a expression and 
abnormal high ER-b: ER-a ratio [76, 77], decreased 
expression and responsivity of PR [78], and hereditary 
genetic polymorphism of drug-metabolizing enzymes 
[216, 217]. 
It is also widely recognized that in both endome-
triosis and cancer, there is co-existence of pathologic 
angiogenesis [218]. Importantly, an increased MMPs 
expression associated to deregulation of the intercel-
lular adherence signaling is identified both in endo-
metriosis pathogeny and in carcinogenesis.
The current knowledge is that two pathways seem 
to be involved in endometriosis and its potential 
progression toward neoplasia: either malignant trans-
formation, probably by an atypical transition stage, 
either the common precursor mechanism or pre-
disposing factors are shared by both processes, with 
a consecutive molecular divergence [219]. Relatively 
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recent histopathological data confirm the possibility 
of transition due to identification of an atypical stage 
and frequent association of ovarian cancer to atypical 
endometriosis. The significance of borderline tumors is 
currently regarded as a part of endometriosis-associated 
ovarian carcinoma spectrum [206, 214, 215]. Moreover, 
recent evidences indicate that patients with endometrio-
sis have a significant risk for endometrial cancer, mainly 
endometrioid and clear cell subtypes [220].
Endometriosis as a precursor lesion
In endometriosis pathogenesis, an important role 
has to be attributed to polygenic susceptibility, which 
implies a metabolic, endocrine, and immune asso-
ciations, responsible for the increase of the number 
of endometrial cells and/or immune surveillance de-
crease and by specific qualities of endometrial cells 
from the peritoneal fluid and/or pelvic inflammation 
[221–223]. Furthermore, the progressive accumu-
lations of genetic alterations of tumor-suppressing 
genes and oncogenes are probably responsible for 
endometriosis development and its possible associ-
ation with the development of malignancies [87–89, 
92, 107, 224, 225].
In numerous studies it was shown that the genetic 
polymorphism is predisposing either to endometri-
osis (e.g. of ICAM-1 or gene promoters of IL-6 and 
IL-10), or to cancer (of genes encoding IL-6, IL-8, 
TNF-a, NFkB-1, and PPAR-g) [52, 216, 225, 226]. 
Moreover, the processes involved in endometriosis 
development are supplemented by genomic instabil-
ity which contributes to the transition to the stage 
of atypical endometriosis. Mutations of genes linked 
to carcinogenesis have been also identified in endo-
metriosis, such as alterations of tumor suppression 
genes [87–98], inactivation of DNA mismatch repair 
genes, by hypermethylation [93], and LOH [87, 107, 
109, 219]. Thus, the next step represented by a tran-
sition or pre-malignant phase, is characterized by 4q, 
5q, 6q, 9p, 11q, 22q, 10q23.3, 17p13.1 LOH [87, 107, 
109, 219], inactivating mutation of PTEN [87–89, 
93, 227, 228], loss of TP53 [90, 91, 107, 228, 229], 
mutations located at multiple loci of beta-catenin, 
and cadherin switch [34, 71, 73, 104], contributing 
to the development of endometrioid and clear cell 
ovarian carcinoma [227–229]. Furthermore, somatic 
mutations in TSG germinal lines may add support 
to this hypothesis [107, 224, 225].
Considering the panel of genetic mechanisms 
which act synergistically contributing to cancer 
genomic instability, with variable overlapping contri-
bution, such as oncogenic activity, TSG inactivation, 
DNA repairing enzymes anomalies, inactivation of 
checkpoints genes of cellular cycle assembly, and 
telomere dysfunctions, some of these pathways have 
to be also detected in precursor lesions. As expected, 
premalignant lesions (atypical endometriosis) are 
characterized by several mutations of tumor suppres-
sor genes, oncogenes, CAMs, and furthermore LOH 
and inflammatory immunomodulation [198]. Table 2 
summarizes the arguments in favor of a common gen-
otype in endometriosis and endometriosis-associated 
ovarian cancers.
Novel approaches and therapeutic  
agents in endometriosis
Acknowledging the role of hormonal stimulation in 
endometriosis, a panel of drugs has been developed 
to modulate the excessive ovarian estrogens synthesis, 
e.g. oral contraceptives (containing an estrogen com-
ponent, such as ethinyloestradiol, mestranol, estradiol 
or its pro-drug estradiol valerate, combined with 
a progestogen, such as levonorgestrel, norethisterone, 
drospirenone, gestodene, desogestrel, nomegestrol, 
dienogest or cyproterone) [248], gestagens [249], 
and danazol ((17a)-Pregna-2,4-dien-20-yno[2,3-d]
isoxazol-17-ol) [19]. Danazol has hormonal action, 
by antigonadotropic action, androgenic activity, and 
interaction with ERs and is also considered a powerful 
immunologic tool in endometriosis, due to its ability to 
decrease immunoglobulins, C3 and C4 complement, 
auto-antibodies against phospholipid antigens, and 
CA-125 levels, as well as its capacity to suppress lym-
phocyte proliferation, along with suppression of IL-1 
and TNF-a production by macrophages [19]. 
The analysis of the common characteristics of 
carcinogenesis and endometriosis development, such 
as sustained proliferative capacity, evasion of growth 
suppressors and of immune destruction, replicative 
immortality, involvement of tumor-promoting in-
flammation, angiogenesis, invasion and metastasis, 
genome instability and mutations, resistance to cell 
death stimuli, and deregulation of cellular energetics, 
lead to the enlargement of the therapeutic arsenal by 
targeting common molecules and molecular pathways 
involved in endometriosis and endometriosis-related 
ovarian cancers [96, 102, 208, 230, 250–256]. 
Thus, by comparing the similar molecular path-
ways identified in both endometriosis and other 
cancers (i.e. breast, ovary, and endometrium cancers), 
a series of anti-cancer agents are currently in different 
clinical trials for endometriosis therapy, awaiting their 
validation. Table 3 documents the progress achieved 
in endometriosis by therapy with anti-cancer agents 
[102, 201, 208, 230–233, 250–259]. Novel therapeutic 
approaches applicable in endometriosis show at least 
five categories of anti-cancer agents that may relate 
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their main action to hormonal substrate, angiogenesis, 
apoptosis, cellular cycle, and immune status. 
Hormonal status is addressed by administration of 
aromatase inhibitors (letrozole, anastrozole) which 
block the conversion of androstendione to estrone, 
creating a low estrogen environment [260]. Another 
approach is to modulate ER activity, either by ER-b 
ligands (CLI or OBHS) already used in clinical prac-
tice [261] or by selective ER modulators (arzoxifene, 
bazedoxifene [262], raloxifene [263]) which are still 
tested in experimental models. In the regulation of 
progesterone action, P4 antagonists (mifepristone, 
RU-486 [264]) and selective PR modulators (aso-
prisnil, BAY 1002670) [265], PF-02413873 [266]) have 
shown promising results in endometriosis therapy in 
either clinical application or in rodent experiments. 
In order to eliminate the systemic side effects, Mirena 
coil (levonorgestrel-releasing intrauterine system) has 
been added to the therapy [267]. In an attempt to reg-
ulate the hypothalamic stimulation of the hormonal 
axis, Gn-RH agonists (elagolix [268], leuprolide, na-
farelin, buserelin, goserelin, triptorelin [269], abarelix 
[270]) showed regression of human endometriotic 
lesions related to hypoestrogenism and, possibly, to 
a supplementary anti-angiogenic activity.
Anti-angiogenesis has been considered as an alter-
native therapeutic approach showing efficacy in endo-
metriosis reduction without side effects on fertility or 
toxicity profiles. Several anti-angiogenic agents have 
been tested in experimental endometriosis. In mouse 
models, rapamycin clearly reduced endometriotic 
implants, along with diminished VEGF expression 
and decreased MVD [271]; in the nude mouse model 
endostatin affected expression of VEGFR2 and/or 
VEGF isoforms and decreased HIF-1a expression 
[272], while angiostatin showed a complex mechanism 
of the inhibition of blood vessel development [273, 
274]; anginex demonstrated anti-angiogenic activity 
in mouse model of endometriosis [274]. In a rat en-
dometriosis model, bevacizumab, VEGF-neutralizing 
monoclonal antibody, was shown to increase apoptosis 
[275]. Other drugs with anti-angiogenic effects con-
firmed in experimental endometriosis are celecoxib, 
a COX-2 inhibitor [276], and non-toxic fumagillin 
analogs, semisynthetic derivatives of a natural antibi-
otic, Aspergillus fumigatus [274]. The results of these 
Table 2. Common molecular features in endometriosis and ovarian cancer
Role Pathway/Molecule Endometriosis Endometriosis — associated 
ovarian cancers
Tumor suppressor ARID1A ± BAF250a mutation
[94, 95, 96, 105, 209, 230–233]
expressed
[105, 233]
expressed
[94, 95, 96, 105, 209, 230–232]
PTEN somatic mutations
[87–89, 93, 227, 228, 234]
expressed
[88, 89, 93, 227, 228]
expressed
[87, 88, 227, 228, 234]
PIK3CA mutations
[96, 104, 207]
early event in endometriosis 
transformation [104]
expressed
[96, 104, 207]
TP53
[90–92, 107, 213, 228, 229]
expressed
(late stages)
[91, 92, 107, 228]
expressed
(advanced stages)
[90, 213, 228, 229]
Oncogene KRAS ±BRAF 
[103, 235]
expressed
(atypical endometriosis)
[103, 235]
expressed
(mucinous type)
[103]
CTNNB1/WNT/b-catenin 
[72, 227, 236, 237]
expressed
(atypical endometriosis)
[72, 237]
expressed
[227, 236]
miRNA profiling miRNA instability 
[238–244]
miR-9
[238–244]
absent
[238]
Microsatellite instability BRCA1/2 [245] absent
–
expressed
[245]
LOH 9p, 11q, 22q [246] expressed
[246]
absent
–
10q23 [109] expressed 
(atypical endometriosis)
[109]
expressed
[109]
Immunomodulation complement pathways 
[247]
expressed
[247]
expressed
[247]
72 Cornelia Amalinei et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2018
10.5603/FHC.a2018.0013
www.fhc.viamedica.pl
experimental studies represent provide hope for the 
application of anti-angiogenic therapies in human 
endometriosis. Promising novel anti-endometriosis 
drugs are represented by the pro-apoptotic agents, 
such as apoptosis inducer (arcyriaflavin) [277], api-
genin [278], NF-kB inhibitor (PDTC), and proteas-
ome inhibitors (bortezomib) [279] that were tested 
on human cell lines and rat models.
Final remarks
Due to endometriosis heterogeneity, attributed to 
genomic and proteomic variability, expressed by var-
iable anatomic location, number, size and duration 
of implants, carcinogenesis associations, numerous 
subtypes of endometriosis have been described.
Current trends in genomic and proteomic ap-
proaches are useful for a deeper understanding of 
endometriosis pathogeny and its malignant trans-
formation, a better (re)classification, and a higher 
potential identification of new therapeutic targets. 
The putative biomarkers such as P450 aromatase, 
IL-6, TNF-a, and anti-endometrial cells autoantibod-
ies have been proposed. 
Nowadays, the therapy is limited by high frequen-
cy of recurrences and the impossibility to preserve 
Table 3. Targeted therapy in endometriosis and endometriosis-associated ovarian malignancies 
Molecules and pathways Effect Therapeutic agent Targeted action
JAK/STAT
[259]
Cell proliferation Leflunomide
Atiprimod
JAK inhibitor
STAT3 inhibitor
TGF-b/SMAD
[201]
Dual roles in regulation cell 
proliferation (balance of 
pro-proliferative and anti-proli-
ferative effects)
Lerdelimumab
Metelimumab
GC-1008
SD-093
LY-580276
Recombinant human IgG4 
targeting TGF-b2
Recombinant human IgG4 
targeting TGF-b1
Targets all TGF-b isoforms
Small molecule inhibitors of 
SMAD2/3 activity
MEK/ERK
[260]
Regulation of signaling for pro-
liferation, apoptosis, adhesion, 
invasion, angiogenesis, and 
evasion of immune surveillance
Selumetinib Small molecular inhibitor of 
MEK
VEGF
[251, 252, 256]
Growth of tumor vessels Bevacizumab Inhibits receptor binding and 
prevent tumor angiogenesis
Sunitinib Multitargeted receptor tyrosine 
kinase inhibitor (VEGFR, 
PDGFR, CD117)
PI3K/AKT/mTOR signaling 
pathway [250]
Lipid kinases that regulate vital 
signaling pathways in neoplasia
RAD001 mTOR inhibitor
Temsirolimus mTOR inhibitor
AnxA4
[255, 261]
Exocytosis and regulation of 
epithelial Cl- secretion
AnxA4-neutralizing antibodies AnxA4 blockade
ARID1A
[230–233]
AT-rich interactive domain 1A 
(SWI-like) gene encodes  
BAF250A (member of the 
SWI/SNF ATP-dependent 
chromatin remodeling  
complex)
EZH2 EZH2 inhibition upregulates 
PI3K which negatively  
regulates PI3K/AKT signals
HNF-1b
[102, 208]
Transcription activator expres-
sed also in endometriosis which 
regulates multiple cancer-rela-
ted genes
Future inhibitors/inhibitors of 
genes activated by HNF-1b 
HNF-1b inhibitor
dipeptidyl peptidase IV inhi-
bitor, osteopontin inhibitor, 
tissue factor pathway inhibi-
tor 2, AnxA4 inhibitor, and 
angiotensin-converting enzyme 
2 inhibitor
ZNF217
[253, 254]
Gene situated on 20q13.2 
encoding a transcription factor 
in cancers associated with poor 
prognosis and lymph node 
metastasis
Triciribine Inhibitor of ZNF127-ove-
rexpressing cells growth
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fertility mainly in women who require extensive 
surgical procedures. Based on molecular analogies 
between endometriosis and carcinogenesis, numerous 
studies are ongoing, being currently during variable 
experimental phases or in clinical trials, as attempts 
to exploit the therapeutic anti-cancer arsenal in the 
treatment of endometriosis. 
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